3.3 Outcomes
At a median follow-up of 38months (range, 34-45months), 3year EFS and OS of the whole cohort were 56.1% (95%CI:50%-56.1%) and 87.8% (95%CI:83%-92.6%). Three-year EFS and OS of the localized cohort were 62% (95%CI:55%-69%) and 88% (95%CI:83%-93%) and of the metastatic cohort were 35% (95%CI:23%-51%) and 88% (95%CI:77%-100%) respectively. Three-year EFS and OS based on TN cut-offs of 100%, 90% and 70% for the whole cohort, localized and metastatic cohorts are detailed in TABLE 2. Survival plots in Fig. 2.